17126-67-9

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-Phenyl-3-hydroxypropionic acid is used as an intermediate in the synthesis of various pharmaceuticals for its pharmacological properties, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
(R)-2-Phenyl-3-hydroxypropionic acid is used as a precursor in the production of agrochemicals, leveraging its ability to form stable complexes with metal ions to enhance the effectiveness of these products.
Used in Cosmetic Industry:
(R)-2-Phenyl-3-hydroxypropionic acid is used as an exfoliant and skin-brightening agent in cosmetic products, taking advantage of its ability to promote skin renewal and improve skin tone.
Used in Topical Skincare Formulations:
(R)-2-Phenyl-3-hydroxypropionic acid is used as an active ingredient in topical skincare formulations for treating acne and other skin conditions due to its demonstrated antibacterial and antiviral activities, making it a potentially useful component in skincare products for managing various skin issues.

Upstream product

• 104266-89-9 (S)-4-benzyl-3-phenylacetyl-2-oxazolidinone 
• 110230-69-8 (S)-1-acetoxy-3-hydroxy-2-phenylpropane 
• 1570-95-2 2-phenylpropane-1, 3-diol 
• 204851-46-7 (S)-4-tert-butyl-3-(2'-phenylacetyl)oxazolidin-2-one 
• 529-64-6 Tropic acid 
• 131682-38-7 (+)-3-acetoxy-2-phenylpropionic acid 
• 3967-53-1 methyl tropate 
• 98017-92-6 2-phenyl-1,3-propanediol diacetate 

Downstream Products

• 105539-02-4 2-(diethylamino)ethyl (R)-(+)-tropate 
• 105539-04-6 2-(diethylamino)ethyl (S)-(-)-tropate 
• 90319-52-1 (4R)-phenyl-2-oxazolidinone 
• 65189-78-8 (-)-2-phenyl-2-carboxyethyl ester of 1-p-chlorobenzoyl-5-methoxy-2-methyl-3-indolylacetic acid 
• 65189-78-8 (+)-2-phenyl-2-carboxyethyl ester of 1-p-chlorobenzoyl-5-methoxy-2-methyl-3-indolylacetic acid 
• 105539-05-7 (-)-(S)-2-(diethylamino)ethyl 2-phenyl-3-(tosyloxy)propanoate 
• 105538-99-6 (+)-(R)-2-(diethylamino)ethyl 2-phenyl-3-(tosyloxy)propanoate 
• 165260-55-9 (2R,3'S)-α-(Hydroxymethyl)benzeneacetic acid 1-azabicyclo<2.2.2>oct-3-yl ester 
• 165260-55-9 (2R,3'R)-α-(Hydroxymethyl)benzeneacetic acid 1-azabicyclo<2.2.2>oct-3-yl ester 
• 51-55-8 atropine 

Relevant academic research and scientific papers

PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS

The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Enantioseparation of typical pesticides using cellulose carbamate stationary phases by capillary liquid chromatography

Cellulose-tris(3,5-dimethylphenylcarbamate) was initially synthesized as the chiral selector, then stable coated and bonded chiral stationary phases were prepared, respectively, using aminopropyl-functionalized silica gel as the support media. The prepared stationary phases were used for micro-column chiral separation by self-installed capillary high performance liquid chromatography system. Eighteen kind of chiral compounds including some typical pesticides were tested on both prepared chiral stationary phases and different chromatographic parameters such as resolution and retention time were comparatively investigated.

High-performance liquid chromatography separation of enantiomers of mandelic acid and its analogs on a chiral stationary phase

The enantiomers of mandelic acid and its analogs have been chromatographically separated on a chiral stationary phase (CSP) derived from 4-(3,5-dinitrobenzamido) tetrahydrophenanthrene. The rationale of separations of these compounds is discussed with respect to the method development for determining enantiomeric purity and possibility of obtaining enantiomerically pure materials by high-pressure liquid chromatography. The relationship of analyte structure to the extent of enantiomeric separation has been examined and separation factors (a) are presented for various groups of structurally related compounds. Chiral recognition models have been suggested to account for the observed separations. These models provide mechanistic insights into the chiral recognition process.

Enantiopure tert-butyl(phenyl)phosphine oxide. Chirality-recognition ability and mechanism

When enantiopure tert-butyl(phenyl)phosphine oxide 1 was used as a resolving agent, it showed an acceptable to good chirality-recognition ability for several kinds of racemic carboxylic acids 2. A study on a chirality-recognition mechanism based on X-ray crystallographic analyses of the diastereomeric complexes of 2 with 1 revealed that the complex crystals consisted of helical columns and that 1 was not responsible for the formation of the helical column and occupied a void between the columns; although 1 interacted with 2 via a hydrogen bond to primarily form a pair with 2, the complex crystals were mainly stabilized by the accumulation of weak interactions, such as CH/π, π/π and CH...O interactions, between 1/1, 1/2 and 2/2.

MUSCARINIC RECEPTOR ANTAGONISTS

This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Enzymatic kinetic resolution of tropic acid

A new strategy has been developed for the CAL-B catalysed kinetic resolution of tropic acid by which both enantiomers of tropic acid can be obtained in good enantiomeric excess. (R)-Tropic acid was synthesised with 90% ee and (S)-tropic acid butyl ester in 99% ee by the hydrolysis of tropic acid butyl ester. The other enantiomers were available through the enzymatically catalysed reaction of tropic acid lactone with butanol to give (S)-tropic acid lactone and (R)-tropic acid ester in >98% ee.

Markedly enhancing enzymatic enantioselectivity in organic solvents by forming substrate salts

A new approach is proposed to enhance enzymatic enantioselectivity in organic solvents. It is based on the presumption that the less reactive substrate enantiomer experiences greater steric hindrances in the enzyme- bound transition state than the more re